Company: CMND
Filing Date: 2025-12-03
Form Type: 424B5
Source: 0001213900-25-117534
Chunk: 9

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-03
Form: 424B5
Chunk 9
---
 our plan will be accepted or we will be able to regain compliance with the Minimum Stockholders’ Equity.

As previously announced,
on September 17, 2025, we entered into securities purchase agreements (the “SPAs”) with investors (the “CLA Investors”)
pursuant to which we shall issue and sell, from time to time, convertible promissory notes (the “Promissory Notes”) in the
aggregate principal amount of up to $10,000,000 (the “Subscription Amount”). As of the date hereof, we have issued Promissory
Notes in the aggregate principal amount of $2.5 million, of which an aggregate of $2.2 million of outstanding amounts due under the Promissory
Notes were converted into 4,135,000 Common Shares. In addition, in November 2025, we raised approximately $5.644 million in a registered
direct offerings of common shares and pre-funded warrants (see “Recent Developments—November 2025 Registered Direct Offerings”
below for additional information), and as of December 2, 2025, we issued 2,090,987 common shares as a result of the exercises for cash
and on a cashless basis of warrants to purchase 2,894,769 common shares, which were previously classified as a liability given certain
of their contractual terms which precluded equity classification, that were issued in our financings in in April 2023 and January 2024
for aggregate gross proceeds of approximately $183,000 (see “Recent Developments—Warrant Exercises” below for additional
information). We expect that we will be able to demonstrate compliance with the Nasdaq stockholders’ equity requirement as a result
of this offering and the aforementioned financing and warrant exercises.

November 2025 Registered Direct Offerings

First November 2025 Registered Direct Offering

On November 13, 2025, we entered into a securities purchase agreement with investors for the purchase and sale of (i) 958,222 common shares, and (ii) pre-funded warrants to purchase up to 2,984,146 common shares, in a registered direct offering, or the November 2025 Offering, at a purchase price of $0.20 per common share and $0.1999 per pre-funded warrant.

The pre-funded warrants are immediately exercisable at an exercise price of $0.0001 per common share, subject to adjustment as set forth therein, and will not expire until exercised in full